Regulatory bodies such as the FDA contribute to the efficient transition of promising new therapies from preclinical research into human testingrummy slots by streamlining this process through designated slots. In treatment settings where time is of the essence, like oncology or infectious diseases, this acceleration is especially crucial. Also, the availability of IND slots pushes drug development firms to take more creative approaches.
